OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Want to cut your energy bills? Here’s how five experts are doing it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
DURHAM, N.C., Feb. 23, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2017 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2016, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 77533539. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
